Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 24, 2007. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility connected to the company's US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to the transaction price of Ordinary Share ADRs, which was $59.35 per share on April 20, 2007.
Material Changes
There are no material changes to the company's financial position or operations reported in this document. The filing details specific changes in the notional allocation of Ordinary Share ADRs within the US Retirement Savings Plan:
- An increase in notional allocation for Mrs. C Bruck Slaoui.
- A decrease in notional allocation for Dr. R G Greig.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is strictly a regulatory disclosure regarding internal plan transactions.
Key Facts for Investor Verification
- Transaction Date: April 20, 2007.
- Share Price: $59.35 per Ordinary Share ADR.
- Involved Parties: Mrs. C Bruck Slaoui (increase) and Dr. R G Greig (decrease).
- Context: Re-valuation of the cash element within the US Retirement Savings Plan.